ITM-11 177Lu-edotreotide Updated Oct 24
Monitor the Telix shareholder vote on December 1, 2026 for the ITM merger, approval is the key near-term catalyst for ITM-11's path forward. Post-merger, watch for regulatory submission plans for ITM-11 in GEP-NETs, which would compete with Novartis' Lutathera. The elevated short volume (~63% weighted ratio) suggests significant bearish positioning that could amplify a positive vote outcome.
- ITM-11 has completed Phase 3 development, de-risking the asset significantly compared to earlier-stage pipeline programs. The COMPETE trial data provides a foundation for regulatory filings.
- The ITM merger gives Telix vertical integration with commercial-scale lutetium-177 production capabilities, a key competitive advantage in the radiopharmaceutical space where isotope supply is a bottleneck.
- Telix has a strong commercial track record (Q3 2026 revenue $245M, +19% YoY) and a proven ability to gain FDA approvals (Pixclara for glioma, Illuccix/Gozellix for prostate cancer), providing a commercial infrastructure to launch ITM-11.
- ITM-11 would compete directly with Novartis' Lutathera (177Lu-dotatate), which is already approved and established as the standard-of-care PRRT for GEP-NETs, creating a significant commercial adoption hurdle.
- The ITM merger ($1.65B upfront + $700M milestones) introduces integration risk and potential shareholder dilution, ITM shareholders will own 23.7% of the combined entity.
- Elevated short volume (~63% weighted short-volume ratio over 28 sessions) indicates significant bearish positioning, suggesting skepticism about the merger value or ITM-11's competitive positioning.